Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 36, 2018 (suppl; abstr LBA4)
Is aanpassing van de bestralingsdosis mogelijk op basis van de genomische stralengevoeligheid van de tumor?
sep 2017 | Radiotherapie